CLEARBRIDGE HEALTH LIMITED INTERIM

Financial Statements

The Group’s finance costs increased to S$0.60 million in 3Q2019, mainly due to interest expense incurred on the bank loans taken up by the Group for its acquisitions, interest expense incurred on the finance lease for assets used in the provision of laboratory services and interest charged on the Convertible Bonds issued by the Company in March 2019 and May 2019. Overall, after taking into account fair value losses in associate and derivative financial instruments of S$2.41 million and S$2.69 million respectively in 3Q2019, the Group registered a net loss of S$6.89 million in 3Q2019. Excluding total fair value losses of S$5.10 million & non-recurring operating expenses of S$0.45 million, the Group would have recorded positive EBITDA of S$0.38 million. It is worth noting that the fair value losses related to associate and derivative financial instruments are non-cash components. On an adjusted EBITDAR basis (which excludes reversal of expected credit losses on accounts receivables of S$1.06 million made by IGM Labs), the Group has continued to lower its quarterly loss, and in 3Q2019, it was lower at $0.68 million, as compared to a loss of S$1.12 million and S$0.88 million recorded in 3Q2018 and 2Q2019 respectively. As of 30 September 2019, the Group’s financial position remained healthy with total assets increasing to S$99.92 million with cash at banks and short-term deposits of S$15.10 million. Commenting on the 3Q2019 results, Mr Jeremy Yee (余斌), Executive Director and Chief Executive Officer of Clearbridge, said, “Our record revenue achieved in this quarter reinforces the coherence of our EBITDA-focused business strategy and strong operational execution. We have made substantial progress in the execution of our strategic priorities to build unique value propositions in high-growth healthcare segments in Asia. With our strategic focus in precision medicine, 2019 will be another step forward in our commitment to deliver sustainable profitable growth.” – END – Issued on behalf of Clearbridge Health Limited by 8PR Asia Pte Ltd. Media & Investor Contacts: Mr. Alex TAN Mobile: +65 9451 5252 Email: [email protected] About Clearbridge Health Limited (Bloomberg Code: CBH:SP / Reuters Code: CLEA.SI / SGX Code: 1H3) Clearbridge Health Limited is a healthcare company with a focus on the delivery of precision medicine in Asia. Its business comprises healthcare syst